We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.2931 | 0.88% | 33.6431 | 33.655 | 33.25 | 33.29 | 4,549,149 | 17:04:24 |
From Nov 2019 to Nov 2024
10:03 ET - GlaxoSmithKline falls more than 7% on the New York Stock Exchange after announcing the purchase of a cancer biotech. Glaxo says it will pay $5.1B for Tesaro, which sells a cancer drug, named Zejula, for treatment of ovarian cancer. The deal helps Glaxo gain a foothold in the lucrative cancer-drugs market. But Zejula's sales have lagged other drugs in its class, known as Parp inhibitors, notably AstraZeneca's Lynparza. And doctors and industry officials say Zejula's side-effect profile is worse than other Parps. (jonathan.rockoff@wsj.com; @jonathanrockoff)
(END) Dow Jones Newswires
December 03, 2018 10:18 ET (15:18 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
